MedTrace Logo

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

NCT04804813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 388

Last updated 2025-04-11

Study results available
· View outcomes & findings →

Summary

This study is a survey in Japan of Cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with renal cell carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 26 weeks.

Conditions

Interventions

DRUG

Cabozantinib

Cabozantinib tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-29
Primary Completion
2024-07-25
Completion
2024-07-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04804813 on ClinicalTrials.gov